Novo Nordisk's Keenly Awaited Semaglutide Trial To ‘Redefine’ Alzheimer’s?

Late-Stage EVOKE Set To Complete September 2025

Semaglutide trial to assess GLP-1 impact on neuro-inflammation • Source: Alamy

More from Clinical Trials

More from R&D